Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recurrent ovarian cancer.

Mohan K Tummala1, William P McGuire

  • 1Greenbaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA. mtummala@umm.edu

Clinical Advances in Hematology & Oncology : H&O
|October 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Phase Ib Study of Indirect Immunization with Oregovomab and Toll-like-Receptor-3 Stimulation with Hiltonol<sup>®</sup> in Patients with Recurrent Platinum-Resistant Ovarian Cancer.

Current oncology (Toronto, Ont.)·2025
Same author

A phase 1 study of regorafenib and sildenafil in adults with advanced solid tumors.

Anti-cancer drugs·2024
Same author

Evaluation of cell-free DNA approaches for multi-cancer early detection.

Cancer cell·2022
Same author

Take me to your leader: Reporting structures and equity in academic gynecologic oncology.

Gynecologic oncology·2020
Same author

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2019
Same author

Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.

American journal of clinical oncology·2019

Recurrent ovarian cancer requires ongoing treatment despite initial chemotherapy success. This review examines evidence-based strategies for managing recurring ovarian cancer, including treatment timing and agent selection.

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Cancer Therapeutics

Background:

  • Ovarian cancer is a leading cause of death from gynecologic malignancies.
  • While initially responsive to chemotherapy (e.g., platinum and taxane doublets), 75% of patients experience relapse within two years.
  • Recurrent ovarian cancer is increasingly viewed as a chronic condition necessitating sequential treatment approaches.

Purpose of the Study:

  • To review current evidence and ongoing clinical trials for treating recurrent ovarian cancer.
  • To address controversies in salvage therapy timing, agent selection, and treatment regimens (monotherapy vs. combination).
  • To discuss the unresolved role of the CA125 tumor marker in recurrence detection and response assessment.

Main Methods:

  • Literature review focusing on evidence from available studies.

Related Experiment Videos

  • Analysis of current clinical trial data for recurrent ovarian cancer management.
  • Discussion of controversial aspects in recurrent ovarian cancer treatment.

    • Main Results:

    • High initial response rates to chemotherapy are often followed by frequent relapses.
    • Significant controversies exist regarding optimal treatment strategies for recurrent disease.
    • The utility of CA125 monitoring in recurrent ovarian cancer remains under investigation.

    Conclusions:

    • Sequential therapy is crucial for managing recurrent ovarian cancer as a chronic disease.
    • Further research and clinical trials are needed to resolve treatment controversies.
    • Clarifying the role of CA125 is essential for improved patient management.